
- /
- Supported exchanges
- / US
- / HOOK.NASDAQ
Hookipa Pharma Inc (HOOK NASDAQ) stock market data APIs
Hookipa Pharma Inc Financial Data Overview
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform. The company's immuno-oncology pipeline includes HB-700, a novel next-generation multi-KRAS mutant-targeting investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers; Eseba-vec, an investigational immunotherapeutic agent in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers with enrollment completed in a Phase 1/2 clinical trial; and HB-300, which targets self-antigens for the treatment of prostate cancer. It is also developing HB-400 for the treatment of Hepatitis B that is in Phase I of clinical trial; and HB-500 for the treatment of Human Immunodeficiency Virus (HIV) that is in Phase I of clinical trial. The company has a collaboration and license agreement with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products for the treatment, cure, diagnosis, or prevention of the hepatitis B virus (HBV) and the HIV. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Hookipa Pharma Inc data using free add-ons & libraries
Get Hookipa Pharma Inc Fundamental Data
Hookipa Pharma Inc Fundamental data includes:
- Net Revenue: 9 351 K
- EBITDA: -72 401 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-07
- EPS/Forecast: -1.04
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Hookipa Pharma Inc News

HOOKIPA Pharma to delist from Nasdaq and liquidate following Gilead asset sale
* HOOKIPA Pharma (NASDAQ:HOOK [https://seekingalpha.com/symbol/HOOK]) announced voluntary delisting from the Nasdaq Capital Market. * The company also intends to deregister its common stock and su...


HOOKIPA Pharma to delist from Nasdaq amid asset sale to Gilead
NEW YORK/VIENNA - HOOKIPA Pharma Inc. (NASDAQ:HOOK), a micro-cap biotech company with a market value of $14.6 million that has seen its stock decline 82% over the past year, announced Friday its inten...

HOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common Stock
NEW YORK and VIENNA, July 18, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”), a clinical-stage biopharmaceutical company developing next-generation immunotherapeutics for...

Gilead (GILD) to Acquire HOOK for $10 million
Gilead Sciences Inc. (NASDAQ:GILD) has announced it will be taking over HOOKIPA Pharma Inc. (NASDAQ:HOOK) for a consideration of $10 million.Gilead (GILD) to Acquire HOOK for $10 million Gilead Scie...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.